Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?

The Omicron variant of SARS-CoV-2 is emerging in communities where people were previously infected with SARS-CoV-2 and are now being vaccinated, or where many people have received two or three coronavirus vaccination doses. More than 130 countries around the globe have implemented booster dose progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chavda, Vivek P., Apostolopoulos, Vasso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950261/
https://www.ncbi.nlm.nih.gov/pubmed/35334999
http://dx.doi.org/10.3390/vaccines10030367
_version_ 1784675098554269696
author Chavda, Vivek P.
Apostolopoulos, Vasso
author_facet Chavda, Vivek P.
Apostolopoulos, Vasso
author_sort Chavda, Vivek P.
collection PubMed
description The Omicron variant of SARS-CoV-2 is emerging in communities where people were previously infected with SARS-CoV-2 and are now being vaccinated, or where many people have received two or three coronavirus vaccination doses. More than 130 countries around the globe have implemented booster dose programs for tackling omicron endemics. Despite early findings shows that booster doses may improve omicron protection, more research is needed to establish vaccination efficacy. This short communication tries to critically discuss the research work findings around booster dose strategy for omicron endemics.
format Online
Article
Text
id pubmed-8950261
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89502612022-03-26 Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2? Chavda, Vivek P. Apostolopoulos, Vasso Vaccines (Basel) Communication The Omicron variant of SARS-CoV-2 is emerging in communities where people were previously infected with SARS-CoV-2 and are now being vaccinated, or where many people have received two or three coronavirus vaccination doses. More than 130 countries around the globe have implemented booster dose programs for tackling omicron endemics. Despite early findings shows that booster doses may improve omicron protection, more research is needed to establish vaccination efficacy. This short communication tries to critically discuss the research work findings around booster dose strategy for omicron endemics. MDPI 2022-02-26 /pmc/articles/PMC8950261/ /pubmed/35334999 http://dx.doi.org/10.3390/vaccines10030367 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Chavda, Vivek P.
Apostolopoulos, Vasso
Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
title Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
title_full Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
title_fullStr Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
title_full_unstemmed Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
title_short Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
title_sort is booster dose strategy sufficient for omicron variant of sars-cov-2?
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950261/
https://www.ncbi.nlm.nih.gov/pubmed/35334999
http://dx.doi.org/10.3390/vaccines10030367
work_keys_str_mv AT chavdavivekp isboosterdosestrategysufficientforomicronvariantofsarscov2
AT apostolopoulosvasso isboosterdosestrategysufficientforomicronvariantofsarscov2

Ejemplares similares